FDG-PET on the Trail of an Unsuspected Primary Malignancy in the Breast
- 1 March 2008
- journal article
- case report
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 33 (3), 175-180
- https://doi.org/10.1097/rlu.0b013e318162ddee
Abstract
Proper identification of the primary malignancy can radically alter clinical management for the patient's benefit. This is a report of an unsuspected primary breast cancer in a patient being worked up for presumptive lymphoma. Prior investigation of lymphedema in the left lower extremity found widespread lymphadenopathy on computed tomography imaging, leading to initial biopsy revealing adenocarcinoma of unknown primary. F-18 fluorodeoxyglucose PET/computed tomography altered management by localizing an F-18 fluorodeoxyglucose avid breast nodule, directing breast biopsy with specific immunohistochemical analysis for breast cancer lineage in metastatic adenocarcinoma. The patient responded well to breast cancer-targeted chemotherapy.Keywords
This publication has 5 references indexed in Scilit:
- Evolving role of positron emission tomography in breast cancer imagingSeminars in Nuclear Medicine, 2005
- Unknown Primary Tumors: Detection with Dual-Modality PET/CT—Initial ExperienceRadiology, 2005
- Head and Neck Cancer: Clinical Usefulness and Accuracy of PET/CT Image FusionRadiology, 2004
- Breast Imaging With Positron Emission Tomography and Fluorine-18 Fluorodeoxyglucose: Use and LimitationsJournal of Clinical Oncology, 2000
- Association between [ 18 F]fluorodeoxyglucose uptake and postoperative histopathology, hormone receptor status, thymidine labelling index and p53 in primary breast cancer: a preliminary observationEuropean Journal of Nuclear Medicine and Molecular Imaging, 1998